RxDoctor Payments Data

Gene Green, MD

Family Medicine · Glen Burnie, MDNPI 1154314326

Payments from drug & device makers

$10,334in general payments, 2019–2025

Across 560 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$722
  • AstraZeneca$581
  • Amgen$535
  • AbbVie$527
  • Boehringer Ingelheim$522
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$10,08998%
  • Education$120%
  • Other$2332%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk125$2,308
Lilly USA, LLC47$722
AstraZeneca33$581
Amgen(2 entities)31$535
AbbVie(2 entities)29$527
Boehringer Ingelheim27$522
Pfizer28$476
Johnson & Johnson18$372
GSK17$321
Merck16$274
Viiv Healthcare Company12$272
Daiichi Sankyo Inc.15$260
Optinose US, Inc.15$252
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC13$226
Lundbeck LLC11$219
Sanofi-aventis U.S. LLC13$195
Dexcom, Inc.8$159
Bayer7$136
Exact Sciences6$123
Baxter Healthcare1$117
Welch Allyn1$117
Gilead6$117
Amarin Pharma, Inc.7$109
Organon4$89
Corcept Therapeutics5$89
Astellas Pharma US Inc4$85
Eisai Inc.5$81
Takeda Pharmaceuticals U.S.A., Inc.5$77
Axsome Therapeutics, Inc.3$62
Vertos Medical, Inc.1$59
Biohaven Pharmaceutical Holding Company Ltd.3$58
Idorsia Pharmaceuticals US Inc3$57
Biogen2$55
Abbott2$48
Biohaven Pharmaceuticals, Inc.3$46
Jazz Pharmaceuticals Inc.2$43
Medtronic3$42
Dynavax Technologies Corporation2$40
Novartis2$36
Tris Pharma Inc2$33
Neuronetics, Inc.2$33
Endo Pharmaceuticals Inc.2$31
Otsuka America Pharmaceutical, Inc.1$25
Radius Health, Inc.1$24
Arbor Pharmaceuticals, Inc.2$24
Sumitomo Pharma America, Inc.1$23
Bausch Health US, LLC1$21
Siemens Medical Solutions USA, Inc.1$20
Corium, LLC1$20
Kyowa Kirin, Inc.1$19
Nevro Corp.1$18
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$18
Therapeuticsmd, Inc.1$18
Xeris Pharmaceuticals, Inc.1$17
Teva Pharmaceuticals USA, Inc.1$17
Tactile Systems Technology Inc1$15
Azurity Pharmaceuticals, Inc.1$14
Ironwood Pharmaceuticals, Inc1$14
Hikma Pharmaceuticals USA1$13
Currax Pharmaceuticals LLC1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,334 in reported general payments places this provider in the 90th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$191,299
Medicare patients
392
Services billed
5,685

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide28$60,497
JardianceEmpagliflozin39$52,638
EliquisApixaban34$45,456
XareltoRivaroxaban23$28,613
FarxigaDapagliflozin Propanediol16$26,190
MounjaroTirzepatide13$25,689
JanuviaSitagliptin Phosphate11$13,098
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$12,468
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$8,722
V-Go 20Sub-Q Insulin Device, 20 Unit11$5,512
Atorvastatin Calcium314$5,033
Budesonide11$4,872
Rosuvastatin Calcium150$4,679
Celecoxib14$4,272
Levemir FlexpenInsulin Detemir13$3,662

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,308$60,49728 claims
Boehringer IngelheimJardiance$522$52,63839 claims
PfizerEliquis$476$45,45634 claims
Johnson & JohnsonXarelto$372$28,61323 claims
AstraZenecaFarxiga$581$26,19016 claims
Lilly USA, LLCMounjaro$722$25,68913 claims
MerckJanuvia$274$13,09811 claims
GSKTrelegy Ellipta$321$12,46812 claims
AbbVieSynthroid$527$3,43841 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Glen Burnie

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →